期刊
CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 68, 期 5, 页码 1363-1367出版社
SPRINGER
DOI: 10.1007/s00280-011-1718-5
关键词
Trabectedin; Ecteinascidin; Pharmacokinetics; Hemodialysis; End-stage renal disease; Dialysis
The pharmacokinetics of trabectedin has never been reported in patients with impaired renal function or in patients on hemodialysis. We examined trabectedin PK in a patient on hemodialysis, starting trabectedin therapy at a standard dose for recurrence of a retroperitoneal myxoid liposarcoma that had occurred under immunosuppressive drugs for kidney transplant. As compared with a population with normal renal function, the study patient presented a higher C (max) and AUC, with lower clearance, terminal half-life, and volume of distribution. The low dialysis clearance, accounting for a minor part of the total body clearance and the absence of detectable trabectedin in the dialysate samples, suggests that hemodialysis does not efficiently clear trabectedin. Trabectedin tolerance was good. This case reports for the first time the feasibility of trabectedin therapy in a hemodialyzed patient. Given the rising incidence of cancer in patients with end-stage renal disease, it is crucial to provide data that improve the management of anticancer drugs in dialyzed patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据